Market closed
Sensei Biotherapeutics/$SNSE
Sensei Biotherapeutics shares are trading lower after the company reported its Q1 2025 financial results.
24 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sensei Biotherapeutics
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
Ticker
$SNSE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15
Website
SNSE Metrics
BasicAdvanced
$10M
-
-$1.20
0.20
-
Price and volume
Market cap
$10M
Beta
0.2
52-week high
$0.76
52-week low
$0.25
Average daily volume
5.5M
Financial strength
Current ratio
7.696
Quick ratio
7.587
Long term debt to equity
3.978
Total debt to equity
10.017
Interest coverage (TTM)
-344.03%
Management effectiveness
Return on assets (TTM)
-32.32%
Return on equity (TTM)
-58.40%
Valuation
Price to book
0.26
Price to tangible book (TTM)
0.26
Price to free cash flow (TTM)
-0.402
Growth
Earnings per share change (TTM)
-1.58%
3-year earnings per share growth (CAGR)
-3.30%
SNSE News
AllArticlesVideos
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
GlobeNewsWire·1 day ago
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
GlobeNewsWire·1 month ago
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sensei Biotherapeutics stock?
Sensei Biotherapeutics (SNSE) has a market cap of $10M as of May 07, 2025.
What is the P/E ratio for Sensei Biotherapeutics stock?
The price to earnings (P/E) ratio for Sensei Biotherapeutics (SNSE) stock is 0 as of May 07, 2025.
Does Sensei Biotherapeutics stock pay dividends?
No, Sensei Biotherapeutics (SNSE) stock does not pay dividends to its shareholders as of May 07, 2025.
When is the next Sensei Biotherapeutics dividend payment date?
Sensei Biotherapeutics (SNSE) stock does not pay dividends to its shareholders.
What is the beta indicator for Sensei Biotherapeutics?
Sensei Biotherapeutics (SNSE) has a beta rating of 0.2. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.